Following a meeting with Actavis’ management, analysts at Sterne Agee increased the earnings estimates and price target on Actavis plc ACT.
Analyst Shibani Malhotra stated,”we raise the price target from $255 to $272 and remain buyers of Actavis on a fundamental basis.”
Analysts also raised third and fourth quarter 2014 earnings estimates to $3.03 per share and $3.41 per share.
Full year 2014 EPS estimates were raised to $13.25 from $13.02.
In addition, Actavis's Watson Labs Dorzolamide Hydrochloride, Timolol, Maleate ANDA was approved by the FDA.
Shares of Actavis are traded recently at $231.01, up 1.08 percent.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.